Tegileridine

Tegileridine is a drug which acts as a μ-opioid receptor agonist. It is closely related to compounds such as oliceridine, TRV734, and SHR9352, and shares a similar profile as a biased agonist selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment.

In January 2024, tegileridine was approved in China for the treatment of moderate to severe pain after abdominal surgery.